Azeliragon

Drug Profile

Azeliragon

Alternative Names: PF-04494700; PF-4494700; TTP-488

Latest Information Update: 19 Jan 2017

Price : $50

At a glance

  • Originator TransTech Pharma
  • Developer Pfizer; TransTech Pharma; vTv Therapeutics LLC
  • Class Antidementias; Diethylamines; Imidazoles; Small molecules
  • Mechanism of Action Advanced glycosylation end-product receptor antagonists; Amyloid inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Alzheimer's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease
  • Discontinued Diabetic nephropathies

Most Recent Events

  • 01 Dec 2016 vTv Therapeutics initiates enrolment in the phase III STEADFAST trial for Alzheimer's disease in USA and Canada (NCT02916056)
  • 22 Sep 2016 vTv Therapeutics plans the phase III STEADFAST Extension trial for Alzheimer's disease (Treatment-experienced) in USA and Canada (PO) (NCT02916056)
  • 07 Sep 2016 Phase-III clinical trials in Alzheimer's disease (Treatment-experienced) in South Africa, New Zealand, Australia and united Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top